Invuity (IVTY) Receives a Buy from Northland Securities

Northland Securities analyst Suraj Kalia maintained a Buy rating on Invuity (NASDAQ: IVTY) yesterday and set a price target of $6. The company’s shares opened today at $7.35.

According to, Kalia is a 5-star analyst with an average return of 16.1% and a 62.6% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Apollo Endosurgery Inc, and Edwards Lifesciences.

Invuity has an analyst consensus of Hold, with a price target consensus of $7.05.

See today’s analyst top recommended stocks >>

Based on Invuity’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $8.95 million. In comparison, last year the company had a GAAP net loss of $10.39 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Invuity, Inc. is a medical technology company, which engages in the development and marketing of surgical and medical devices. Its products include retractors, handhelds, and drop-ins under the Photonics and PhotonBlade brands. The company was founded by Kenneth B. Trauner and Alex Vayser on November 29, 2004 and is headquartered in San Francisco, CA.

From Our Partners